Edgestream Partners L.P. Buys Shares of 53,738 TG Therapeutics, Inc. (NASDAQ:TGTX)

Edgestream Partners L.P. bought a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 53,738 shares of the biopharmaceutical company’s stock, valued at approximately $1,618,000.

Other large investors also recently added to or reduced their stakes in the company. E Fund Management Co. Ltd. increased its stake in shares of TG Therapeutics by 7.8% in the fourth quarter. E Fund Management Co. Ltd. now owns 23,554 shares of the biopharmaceutical company’s stock worth $709,000 after acquiring an additional 1,711 shares during the last quarter. Inceptionr LLC acquired a new position in shares of TG Therapeutics in the fourth quarter worth $263,000. Raymond James Financial Inc. acquired a new position in shares of TG Therapeutics in the fourth quarter worth $14,508,000. Arizona State Retirement System increased its stake in shares of TG Therapeutics by 0.9% in the fourth quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company’s stock worth $1,283,000 after acquiring an additional 364 shares during the last quarter. Finally, Proficio Capital Partners LLC acquired a new position in shares of TG Therapeutics in the fourth quarter worth $306,000. 58.58% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics Trading Up 2.1 %

TG Therapeutics stock opened at $39.23 on Tuesday. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The company has a market capitalization of $6.16 billion, a price-to-earnings ratio of -392.26 and a beta of 2.30. TG Therapeutics, Inc. has a one year low of $12.93 and a one year high of $40.31. The company’s fifty day moving average price is $31.23 and its two-hundred day moving average price is $28.67.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company had revenue of $108.19 million during the quarter, compared to analysts’ expectations of $100.67 million. On average, analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the sale, the chief financial officer now directly owns 660,611 shares in the company, valued at $18,847,231.83. This represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 10.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on TGTX. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 4th. JPMorgan Chase & Co. upped their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. Finally, HC Wainwright reissued a “buy” rating and set a $55.00 target price on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.